Other Events ·
Taysha Gene Therapies, Inc. announced the completion of dosing in the REVEAL Pivotal Trial and reported longer-term…
TSHATaysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc. announced the completion of dosing in the REVEAL Pivotal Trial and reported longer-term clinical data from Part A of the REVEAL Phase 1/2 trials evaluating TSHA-102 for Rett Syndrome. The company provided clinical and regulatory updates on TSHA-102 via a press release and a corporate presentation. Taysha Gene Therapies, Inc. is a biotechnology company focused on developing gene therapies for neurodevelopmental disorders.